Checkpoint Therapeutics, Inc. (CKPT) - Forvard P/S multiplikatori
Checkpoint Therapeutics immuno-onkologiya agentlarini kashf qilishni tezlashtirish uchun robototexnika tizimlari va AI texnologiyalarini joriy qilmoqda. Bashorat qilingan P/S koeffitsiyenti joriy bozor bahosini aks ettiradi va ushbu ko'rsatkich 9239.00 darajasida turibdi. Raqamli ma'lumotlar tahlili kompaniyaga global tadqiqotlarni samarali boshqarish imkonini beradi. Bozor ulushini egallash strategiyasi FDA tasdig'idan keyin dori vositasiga chegirmali narxlar belgilashga asoslangan.
Checkpoint Therapeutics Inc (CKPT) moliyaviy va bozor koʻrsatkichlari kesimi
- joriy narx va aksiyalarning prognoz qilingan qiymati:
- bozor kapitallashuvi ko'rsatkichlari:
- emitentning balans qiymati statistikasi:
- qarz va likvidlik bo'yicha ma'lumotlar:
Qarzning xususiy kapitalga nisbati Checkpoint Therapeutics|CKPT - Uzoq muddatli majburiyatlarning o'z kapitaliga nisbati|Qisqa muddatli qarzning o'z kapitaliga nisbati Checkpoint Therapeutics|CKPT - Kompaniyaning umumiy yig'indi qarzi|Balans kapitallashuviga qarzlar Checkpoint Therapeutics Inc|CKPT - Uzoq muddatli qarz hajmi|Kompaniyaning qisqa muddatli qarzi Checkpoint Therapeutics|Tezkor likvidlik ko‘rsatkichi checkpointtx.com
- moliyaviy natijalar va qiymat multiplikatorlari tafsilotlari:
CKPT - Soliqlar to‘langandan keyingi foyda|Kelajakdagi foyda Checkpoint Therapeutics|CKPT - Kompaniya qiymatining sof foydaga nisbati|Prognoz qilingan narxning foydaga nisbati Checkpoint Therapeutics, Inc|CKPT - Kompaniya qiymatining foyda o‘sish sur’atiga nisbati|EV/EBITDA multiplikatori Checkpoint Therapeutics Inc|CKPT - Foizlar, soliqlar va amortizatsiya chegirilmasdan oldingi daromad|Bir aksiya uchun sof foyda (EPS TTM) Checkpoint Therapeutics|CKPT - So'nggi o'n ikki oy davomida bitta aksiya uchun sof foyda|So'nggi o'n ikki oy davomida bir aksiya uchun foydaning yillik o'sishi checkpointtx.com|CKPT - Joriy yilda bir aksiya uchun foyda ortishi|Keyingi yil uchun foyda o'sishi prognozi Checkpoint Therapeutics
- sotuvlar va tushum bo'yicha ma'lumotlar:
Kompaniyaning dastlabki tahlili:Checkpoint Therapeutics, Inc. CKPT
Forward P/S ko'rsatkichi joriy bozor kapitalizatsiyasining kutilayotgan daromadga nisbatini aks ettirib, sotuvlar birligi bo'yicha biznes qiymatiga oid bozor kutuvlari tendentsiyasini ifodalaydi. Checkpoint Therapeutics (CKPT) uchun forward P/S grafigini tahlil qilish orqali investor, dori vositasi FDA tasdig'idan so'ng tijorchashtirish bosqichiga kirgan holda, narxlarni sun'iy ravishda pasaytirish (price dumping) orqali onkologiya bozorini agressiv egallash strategiyasini hisobga olgan holda, aktivlardan yuqori premiumning asoslanganligini baholaydi.
Raqobatdosh kompaniyalar tahlili
Forvard P/S multiplikatori ONC (BeiGene)|Sotuvga nisbatan forvard narx HALO|RevMed - Forvard P/S multiplikatori|Bozor kapitallashuvining kelajakdagi daromadga nisbati Ascentage Pharma Corp|CGON: Forvard P/S multiplikatori|Forvard narx/daromad multiplikatori urogen.com|Narxning prognoz qilingan daromadga nisbati Bicara Therapeutics|Forvard P/S multiplikatori Personalis Inc|Narxning prognoz qilingan daromadga nisbati Erasca Corp (ERAS)|DCTH: Kelajakdagi narxning daromadga nisbati|Narxning prognoz qilingan daromadga nisbati Y-mAbs Therapeutics YMAB|aurabiosciences.com (AURA) - Bozor kapitallashuvining kelajakdagi daromadga nisbati|Candel - Forvard P/S multiplikatori|Kapitalizatsiyaning kutilayotgan sotuvga nisbati Accuray Inc ARAY|sellaslifesciences.com (SLS) - Narxning prognoz qilingan daromadga nisbati|Kapitalizatsiyaning prognoz qilingan daromadga nisbati ACTU|Forvard narx/daromad multiplikatori CTOR|HURA (TuHURA) - Narxning kutilayotgan daromadga nisbati|Forvard narx/daromad multiplikatori TARA (Protara Therapeutics, Inc.)|FATE (Fate Therapeutics Inc) - Sotuvga nisbatan forvard narx|Aadi Bioscience - Forvard narx/daromad multiplikatori|Narxning kutilayotgan daromadga nisbati TCRX (TScan Therapeutics Inc)|Champions Oncology Corp - Forvard P/S multiplikatori|Sotuvga nisbatan forvard narx XBIT (XBiotech Inc.)|CVM: Forvard P/S multiplikatori|Bozor kapitallashuvining kelajakdagi daromadga nisbati OS Therapies Inc. (OSTX)|Narxning prognoz qilingan daromadga nisbati Radiopharm Theranostics Limited|ARTV: Sotuvga nisbatan forvard narx|Forvard P/S multiplikatori ANL|Forvard P/S multiplikatori verupharma.com (VERU)|Narxning prognoz qilingan daromadga nisbati Tempest Therapeutics, Inc. TPST|XLO (Xilio Therapeutics Inc) - Kelajakdagi narxning daromadga nisbati|Enochian BioSciences - Forvard P/S multiplikatori|Bozor kapitallashuvining kelajakdagi daromadga nisbati Mural Oncology plc|KAPA (kairospharma.com) - Forvard narx/daromad multiplikatori|OnKure Therapeutics (OKUR) - Forvard P/S multiplikatori|Forvard narx/daromad multiplikatori GDTC|CRIS (Curis Corp) - Narxning kutilayotgan daromadga nisbati|Forvard P/S multiplikatori APLM|Kapitalizatsiyaning kutilayotgan sotuvga nisbati Tharimmune Corporation|Forvard P/S multiplikatori ADVB (Advanced Biomed)|GNPX - Forvard narx/daromad multiplikatori|CLDI - Narxning prognoz qilingan daromadga nisbati|Kapitalizatsiyaning kutilayotgan sotuvga nisbati Sunshine Biopharma Inc. SBFM|XBIO: Forvard P/S multiplikatori|Forvard narx/daromad multiplikatori Salarius Pharma|Narxning prognoz qilingan daromadga nisbati Purple Biotech|Forvard P/S multiplikatori AON|Narxning prognoz qilingan daromadga nisbati BeiGene (BGNE)|ELEV: Kelajakdagi narxning daromadga nisbati|iCAD - Forvard narx/daromad multiplikatori|Narxning kutilayotgan daromadga nisbati IKNA (Ikena Oncology Inc.)|Notable Labs, Ltd. - Forvard P/S multiplikatori|Viracta Therapeutics (VIRX) - Forvard narx/daromad multiplikatori|MOR: Forvard P/S multiplikatori|NAYA Biosciences Inc (NAYA) - Forvard P/S multiplikatori|Narxning prognoz qilingan daromadga nisbati Ascentage Pharma Group Ltd
